Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism

Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in 2015 for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. It is the fourth target-specific oral anticoagulant to be approved. Edoxaban is noninferior for ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Tellor, Katie B, Van Tuyl, Joseph S, Armbruster, Anastasia L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853158/
https://www.ncbi.nlm.nih.gov/pubmed/27217759
http://dx.doi.org/10.2147/TCRM.S84608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853158/
https://www.ncbi.nlm.nih.gov/pubmed/27217759
http://dx.doi.org/10.2147/TCRM.S84608

Ejemplares similares